ClinicalTrials.gg
RecruitingNCT07439796Updated Apr 16, 2026

A Study of ORN252 in Healthy Participants

A Phase 1 interventional study of ORN252 in Healthy Volunteers - Male and Female, sponsored by Orna Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Orna Therapeutics, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and tolerability of ORN252 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers - Male and Female
03

In context

Lead sponsor

This is the only study on the registry with Orna Therapeutics, Inc. as lead sponsor.

First submitted before Orna Therapeutics, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants who are healthy as determined by the Investigator based on review of medical history, physical examination, and laboratory tests
  • Participant is willing and able to comply with study visits and other protocol requirements
  • Other protocol specific inclusion criteria may apply

Exclusion criteria

Exclusion Criteria:

  • history or presence of organ dysfunction
  • Use of any product within 3 months, or 5 half-lives, whichever longer
  • Other protocol specific exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Single Ascending Dose

    Ascending single dose of ORN252 on a specified day

    Biological: ORN252

Interventions

  • BiologicalORN252

    ORN252 is a lipid nanoparticle encapsulating a circular RNA encoding an anti-CD19 CAR protein.

06

What researchers measure

Primary outcomes

  1. The incidence and severity of safety, clinical, and laboratory abnormalities in healthy adult participants.

    To evaluate the safety and tolerability of ORN252 administered to healthy adult participants.

    Time frame: 12 weeks

Secondary outcomes

  1. Pharmacokinetic (PK) parameters of ORN252 components

    Area under the concentration versus time curve from time zero to the time of the last quantifiable concentration \[AUClast\]

    Time frame: 29 days

  2. Pharmacokinetic (PK) parameters of ORN252 components

    Maximum concentration \[Cmax\]

    Time frame: 29 days

  3. Pharmacokinetic (PK) parameters of ORN252 components

    Time of maximum concentration \[Tmax\]

    Time frame: 29 days

  4. Pharmacokinetic (PK) parameters of ORN252 components

    Terminal elimination half-life \[t1/2\]

    Time frame: 29 days

  5. Pharmacokinetic (PK) parameters of ORN252 components

    Volume of distribution \[Vdss\]

    Time frame: 29 days

  6. Pharmacokinetic (PK) parameters of ORN252 components

    Clearance \[CL\]

    Time frame: 29 days

  7. Pharmacokinetic (PK) parameters of ORN252 components

    Area under the concentration versus time curve from time zero to infinity (AUCinf)

    Time frame: 29 days

  8. Pharmacodynamic (PD) effects of of ORN252

    Changes in circulating B cell counts and lymphocytes

    Time frame: 12 weeks

  9. Immunogenicity of ORN252

    To assess the presence of anti-drug antibodies in healthy adult participants

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 27, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07439796
Responsible party
Sponsor
First posted
Feb 27, 2026
Start date
Mar 16, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Orna Clinical Trials
Contact
ClinicalTrials@ornatx.com
877-728-6762

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion